ACTHERA is a Swiss biotech company founded in 2019. We develop a therapeutic platform based on a unique type of mechano-responsive Hard-Shelled Liposomes (HSLs), to control and target the release of therapeutic molecules, thus improving the efficacy and safety of these therapies. Acute cardiovascular events, such as acute ischemic stroke (AIS) and acute myocardial infarction (AMI) are our LEAD clinical indication, with the encapsulation of therapeutic molecules to decrease the morbidity and mortality of these events. The HSL plateform has a huge potential for development, as many therapeutic molecules can be loaded (small molecules, proteins, nucleic acids) and various external tools can be used to trigger the release of these cargo: the combination of these three elements has the power to profoundly change the efficacy/safety profile of numerous therapies in many disease areas. With our disruptive technology, we want to change the future of drug delivery and medical therapy. If you want to know more, visit our website at https://acthera-therapeutics.com/